TRAJ22: A Protein Implicated in T Cell Recognition (G28733)

Target Name: TRAJ22

NCBI ID: G28733

TRAJ22

Other Name(s): T cell receptor alpha joining 22

TRAJ22: A Protein Implicated in T Cell Recognition

T cell receptor alpha-joining 22 (TRAJ22) is a protein that is expressed in T cells, a type of white blood cell that plays a crucial role in the immune system. T cells are responsible for detecting and responding to foreign substances in the body, and they are an important part of the immune system because they help to fight off infections and diseases.

TRAJ22 is a type of protein that is made up of several different subunits. These subunits are held together by disulfide bonds, which are chemical bonds that form when two proteins come into contact with each other. The subunits of TRAJ22 include a constant (C1) subunit, a variable (V) subunit, and a C-terminal hypervariable region (HVR).

The C1 subunit ofTraj22 is a 24 amino acid protein that is made up of two distinct regions. The first region is a constant region that is the same for all forms ofTraj22. The second region is a variable region that is unique to each form ofTraj22.

The V subunit ofTraj22 is also a 24 amino acid protein. It is similar to the C1 subunit in terms of its structure, but it has a different amino acid sequence. The V subunit is responsible for interacting with the T cell receptor alpha-joining 2 (TRAJ2) protein.

TRAJ22 is a protein that is expressed in T cells, and it is involved in the signaling process that occurs when T cells recognize and respond to foreign substances in the body. It is thought that Traj22 may be a drug target or biomarker because it is involved in the immune response, and drugs that target Traj22 may be effective in treating diseases that are caused by an imbalance of the immune system.

TRAJ22 is a protein that is expressed in T cells, and it is involved in the signaling process that occurs when T cells recognize and respond to foreign substances in the body. It is thought that Traj22 may be a drug target or biomarker because it is involved in the immune response, and drugs that target Traj22 may be effective in treating diseases that are caused by an imbalance of the immune system.

Protein Name: T Cell Receptor Alpha Joining 22

The "TRAJ22 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TRAJ22 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets